Endocyte (ECYT) Misses Q3 EPS by 20c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Endocyte (ECYT) Misses Q3 EPS by 20c

Endocyte Reports Third Quarter Financial Results

November 6, 2017 4:01 PM EST

         Plans to Initiate Phase 3 Registration for 177Lu-PSMA-617 Accelerated by Radiomedix Agreement to Transfer Active U.S. Investigational New Drug Application (IND) to Endocyte

       The University of Sydney and ANZUP Cancer Trial Group Set to Initiate Trial of 177Lu-PSMA-617 versus Cabazitaxel Under Agreement with Endocyte

         CAR T-Cell Program on Schedule to Initiate Clinical Trial in Osteosarcoma in 2018

Conference Call Today at 4:30 p.m. EST

WEST LAFAYETTE, Ind., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ: ECYT), a... More